4-[(5-oxy-quinolinyl-8-amino)carbonylamino-(2-fluoro-5-trifluoromethyl-phenyl)]-pyridin-5,6-imidazolone | 1192261-35-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[(5-oxy-quinolinyl-8-amino)carbonylamino-(2-fluoro-5-trifluoromethyl-phenyl)]-pyridin-5,6-imidazolone
• 英文别名: 1-[2-Fluoro-5-(trifluoromethyl)phenyl]-3-[5-[(2-oxo-1,3-dihydroimidazo[4,5-b]pyridin-7-yl)oxy]quinolin-8-yl]urea
• CAS: 1192261-35-0
• 化学式: C₂₃H₁₄F₄N₆O₃
• 分子量: 498.396
• InChiKey: QOMBDSLLDLQYSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  36
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  117
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  4-(8-N-BOC-amino-quinolinyl-5-oxy)-5,6-diamino-pyridine 在 吡啶 、 三氟乙酸 作用下， 以 四氢呋喃 为溶剂， 反应 22.5h， 生成 4-[(5-oxy-quinolinyl-8-amino)carbonylamino-(2-fluoro-5-trifluoromethyl-phenyl)]-pyridin-5,6-imidazolone
  参考文献：
  名称：

  [EN] ARYL-QUINOLYL COMPOUNDS AND THEIR USE
  [FR] COMPOSÉS ARYL-QUINOLÉYLE ET LEUR UTILISATION

  摘要：

  本发明一般涉及治疗增殖性疾病、癌症等的治疗化合物领域，更具体地涉及本文所述的某些芳基喹啉化合物，该化合物在诸多方面抑制了RAF（例如B-RAF）活性。本发明还涉及包含这种化合物的药物组合物，以及利用这种化合物和组合物在体外和体内抑制RAF（例如BRAF）活性，抑制受体酪氨酸激酶（RTK）活性，抑制细胞增殖，并用于治疗通过抑制RAF、RTK等而得到改善的疾病和疾病，如癌症（例如结直肠癌、黑色素瘤）等。

  公开号：

  WO2009130487A1

文献信息

• ARYL-QUINOLYL COMPOUNDS AND THEIR USE
  申请人：Cancer Research Technology Limited

  公开号：EP2285805B1

  公开（公告）日：2014-07-23
• Aryl-Quinolyl Compounds and Their Use
  申请人：Niculescu-Duvaz Ion

  公开号：US20110053946A1

  公开（公告）日：2011-03-03

  The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain aryl-quinolyl compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.
• US8383816B2
  申请人：——

  公开号：US8383816B2

  公开（公告）日：2013-02-26
• [EN] ARYL-QUINOLYL COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS ARYL-QUINOLÉYLE ET LEUR UTILISATION
  申请人：CANCER REC TECH LTD

  公开号：WO2009130487A1

  公开（公告）日：2009-10-29

  The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain aryl-quinolyl compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.

  本发明一般涉及治疗增殖性疾病、癌症等的治疗化合物领域，更具体地涉及本文所述的某些芳基喹啉化合物，该化合物在诸多方面抑制了RAF（例如B-RAF）活性。本发明还涉及包含这种化合物的药物组合物，以及利用这种化合物和组合物在体外和体内抑制RAF（例如BRAF）活性，抑制受体酪氨酸激酶（RTK）活性，抑制细胞增殖，并用于治疗通过抑制RAF、RTK等而得到改善的疾病和疾病，如癌症（例如结直肠癌、黑色素瘤）等。